Skip to main content
Premium Trial:

Request an Annual Quote

OGI Starts New Fund for High-Risk Genomics Research

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The Ontario Genomics Institute has started a new C$400,000 ($416,000) technology development fund for high-risk, high-impact genomics research.

OGI said today that it plans to use the fund over the next two years to provide four awards of up to $50,000 annually for 12-month research projects that will "result in transformative technology development."

The program will fund projects that focus on developing technologies such as instrumentation, software, experimental approaches, or reagents, and which may have a "significant impact in the genomics sciences," the institute said.

The aim of the program, called SPARK, is to "catalyze new research directions and increase the competitiveness of Ontario researchers," OGI President and CEO Mark Poznansky said in a statement. "Our intention with the launch of this program is to fund projects that may not be readily funded by other mechanisms as they would be viewed as too risky or lacking in preliminary results."

OGI said that it will accept applications for the program through June 15, 2011.

Filed under

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.